
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Myasthenia Gravis Treatment Market**

According to Intelli, the U.S. Myasthenia Gravis Treatment Market size was valued at USD 898.3 Million in 2024 and is projected to reach USD 1,669.86million by 2032, growing at a CAGR of 8.65% from 2025 to 2032.



Myasthenia Gravis (MG) is a rare, chronic autoimmune neuromuscular disorder that disrupts the communication between nerves and muscles, leading to profound and often debilitating muscle weakness. It most commonly affects the eyes, face, throat, and limbs, causing symptoms such as drooping eyelids, difficulty speaking, swallowing, and even breathing in severe cases. Though its progression varies from person to person, MG is often misunderstood or misdiagnosed, delaying critical treatment. The etiological factors of MG are primarily rooted in autoimmune dysfunction. In most cases, the body’s immune system mistakenly produces antibodies that block or destroy acetylcholine receptors at the neuromuscular junction, preventing effective communication between nerves and muscles. Approximately 80-85% of MG patients have detectable anti-acetylcholine receptor (AChR) antibodies, while others may have anti-MuSK (muscle-specific kinase) or anti-LRP4 antibodies, all of which interfere with neuromuscular signaling. The exact cause of this autoimmune response remains unclear, but it is believed to be influenced by a combination of genetic predisposition, environmental triggers, and abnormalities in the thymus gland—such as thymic hyperplasia or thymomas, which are often associated with early-onset MG. Infections, stress, or other autoimmune conditions like thyroid disorders and lupus may also act as catalysts for the disease. While MG can occur at any age, it shows a bimodal distribution, commonly affecting younger women and older men, suggesting hormonal and immunological factors may also play a role in disease onset. Yet, in recent years, breakthroughs in immunotherapy and biologics have transformed the treatment landscape, offering patients not just symptom relief, but renewed hope for a better quality of life.

**U.S. Myasthenia Gravis Treatment Market Definition**

The U.S. Myasthenia Gravis Treatment Market refers to the healthcare segment dedicated to diagnosing, managing, and treating MG using various pharmacological and non-pharmacological methods. These treatments include anticholinesterase agents, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIG), plasma A close-up of hands holding a tablet and a pen

Description automatically generatedexchange, biologics, and emerging gene therapies. This market is influenced by clinical advancements, regulatory approvals, and research on rare disease therapies.

**U.S. Myasthenia Gravis Treatment Market Overview**

The U.S. Myasthenia Gravis treatment market is experiencing significant growth, driven by advancements in targeted therapies, increased disease awareness, and a shift towards patient-centric care. A significant trend shaping the U.S. Myasthenia Gravis treatment market is the increasing adoption of monoclonal antibody (mAb) therapies, particularly for patients with severe or refractory forms of the disease. Therapies like eculizumab (Soliris), which target the complement system involved in the autoimmune response, have shown effectiveness in reducing MG symptoms and improving patient outcomes. Another key development is the FDA approval of a prefilled syringe version of Argenx's Vyvgart, enabling at-home self-administration. This advancement not only enhances patient convenience and adherence but also broadens market accessibility, signaling a shift towards more flexible and patient-friendly treatment options. The market is also influenced by a gradual shift towards novel therapies due to the side effects associated with conventional treatments. This shift, coupled with increasing prevalence and awareness of MG, is leading to higher diagnosis rates and, consequently, a growing number of patients requiring treatment. Furthermore, the emergence of biologics and the approval of promising drugs are contributing to the market's expansion.​Improved access to specialty care and neurologists plays a crucial role in the evolving landscape of MG treatment in the U.S. As awareness of MG grows and healthcare infrastructure advances, patients are increasingly able to consult with neurologists and neuromuscular specialists who are essential for accurate diagnosis and tailored treatment planning. access to specialty care enables the use of advanced diagnostic tools, personalized medicine approaches. This shift towards specialized, expert-driven care contributes to better disease management, improved patient outcomes, and greater integration of novel treatment options into clinical practice.

**U.S. Myasthenia Gravis Treatment Market Segmentation**

The U.S. Myasthenia Gravis Treatment Market is segmented based on drug class, disease type, and end user.

**U.S. Myasthenia Gravis Treatment Market, By Treatment Type**

* **Anticholinesterase Medications**
* A close-up of hands holding a tablet and a pen

  Description automatically generated**Pyridostigmine**
* **Corticosteroids**
* **Prednisone**
* **Immunosuppressants**
* **Azathioprine**
* **Mycophenolate mofetil**
* **Cyclosporine**
* **Monoclonal Antibodies (Biologics)**
* **Eculizumab (Soliris)**
* **Ravulizumab (Ultomiris)**
* **IVIG Therapy**
* **Plasmapheresis / Plasma Exchange (PLEX)**
* **Surgical Treatment**
* **Thymectomy**

The U.S. Myasthenia Gravis treatment market is dominated by anticholinesterase medications, with pyridostigmine continuing to serve as the first-line therapy for symptomatic management, accounting for a significant portion of the market share due to its long-standing clinical utility and widespread availability. However, the monoclonal antibody segment, particularly biologics like eculizumab and ravulizumab is experiencing the fastest growth, driven by their efficacy in treating refractory generalized MG and their FDA approvals for targeted use. Immunosuppressants such as azathioprine and mycophenolate mofetil maintain a strong presence in long-term management strategies, while IVIG therapy and plasmapheresis/PLEX are primarily utilized for acute exacerbations and crisis management. Surgical treatment, including thymectomy, continues to play a critical role in selected patients, especially those with thymoma or early-onset generalized MG. The evolving therapeutic landscape, coupled with innovations in biologics, is reshaping the market dynamics, making targeted and personalized therapies increasingly central to MG management.

**U.S. Myasthenia Gravis Treatment Market, By Disease Type**

* A close-up of hands holding a tablet and a pen

  Description automatically generated**Ocular Myasthenia Gravis**
* **Generalized Myasthenia Gravis**
* **Congenital Myasthenic Syndrome**
* **Transient Neonatal Myasthenia Gravis**

The U.S. Myasthenia Gravis treatment market is further segmented by disease type, each requiring specialized treatment approaches. Generalized Myasthenia Gravis holds the largest market share due to its prevalence and the need for advanced therapies, including monoclonal antibodies and immunosuppressants, which are critical for managing severe and refractory cases. Although smaller in market share, Congenital Myasthenic Syndrome and Transient Neonatal Myasthenia Gravis are critical subsegments, with CMS demanding specialized treatments due to its hereditary nature, and TNMG typically requiring supportive care.

**U.S. Myasthenia Gravis Treatment Market, By End User**

* **Hospitals**
* **Specialty Neurology Clinics**
* **Homecare Settings**
* **Academic & Research Institutes**

The U.S. Myasthenia Gravis treatment market is segmented by end user, with each segment playing a crucial role in the delivery of care. Hospitals dominate the market, accounting for the largest share due to their comprehensive facilities for treating acute exacerbations, surgeries like thymectomy, and the administration of complex treatments such as IVIG therapy and plasmapheresis. Specialty neurology clinics are also significant contributors, especially with the growing demand for specialized care and the management of chronic and refractory cases of Myasthenia Gravis, including the use of monoclonal antibodies and immunosuppressants. The homecare settings segment is expanding rapidly, driven by the convenience and increased patient preference for at-home treatments like self-administration of biologics and oral medications. This shift is enhancing patient comfort and broadening access to care. Lastly, academic and research institutes play a vital role in the development of novel therapies and ongoing research into MG treatments, thereby supporting future market growth and innovation. The market dynamics are evolving, with a shift towards outpatient and home-based care, making it a more patient-centric ecosystem.

A close-up of hands holding a tablet and a pen

Description automatically generated**Key Players**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe “U.S. Myasthenia Gravis Treatment Market " study report will provide valuable insight emphasizing the U.S. market. The major players in the market Alexion Pharmaceuticals, Inc., Horizon Therapeutics, CSL Behring, Grifols S.A., argenx SE, Roche Holding AG, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc.,Kezar Life Sciences, UCB Pharma, Amgen Inc., Astellas Pharma Inc.,Novartis AG, GlaxoSmithKline plc, Biogen Inc., Genentech, Inc. among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In March 2024, Zilucoplan, a complement C5 inhibitor developed by UCB Pharma, was approved by FDA. It is used in the treatment of generalized myasthenia gravis in adult patients, marking a significant step forward in targeted autoimmune therapy.
* A standout advancement in 2024 was the continued clinical progress of batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). This novel mechanism reduces pathogenic IgG autoantibodies, which are central to the progression of MG.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Myasthenia Gravis Treatment Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in U.S. Myasthenia Gravis Treatment Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. MYASTHENIA GRAVIS TREATMENT MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. MYASTHENIA GRAVIS TREATMENT MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY TREATMENT TYPE**

5.1 Overview

5.2 Anticholinesterase Medications

A close-up of hands holding a tablet and a pen

Description automatically generated 5.2.1 Pyridostigmine

5.3 Corticosteroids

5.3.1 Prednisone

5.4 Immunosuppressants

5.4.1 Azathioprine

5.4.2 Mycophenolate mofetil

5.4.3 Cyclosporine

5.5 Monoclonal Antibodies (Biologics)

5.5.1 Eculizumab (Soliris)

5.5.2 Ravulizumab (Ultomiris)

5.6 IVIG Therapy

5.7 Plasmapheresis / Plasma Exchange (PLEX)

5.8 Surgical Treatment

5.8.1 Thymectomy

**6 U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISEASE TYPE**

6.1 Overview

6.2 Ocular Myasthenia Gravis

6.3 Generalized Myasthenia Gravis

6.4 Congenital Myasthenic Syndrome

6.5 Transient Neonatal Myasthenia Gravis

**7 U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY END-USER**

7.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated 7.2 Hospitals

7.3 Specialty Neurology Clinics

7.4 Homecare Settings

7.5 Academic & Research Institutes

1. **U.S. MYASTHENIA GRAVIS TREATMENT MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 Alexion Pharmaceuticals, Inc.**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Horizon Therapeutics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **CSL Behring**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  3. **Grifols S.A**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **argenx SE**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Roche Holding AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Bausch Health Companies Inc**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments

* 1. **Octapharma AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Kezar Life Sciences**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **UCB Pharma**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Amgen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Astellas Pharma Inc.**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  6. **Novartis AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **GlaxoSmithKline plc,**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Biogen Inc**

9.16.1Overview

* + 1. Financial Performance
    2. Product Outlook
    3. Key developments
  1. **Genentech, Inc.**

9.17.1 Overview

* + 1. Financial Performance
    2. Product Outlook
    3. Key developments

1. A close-up of hands holding a tablet and a pen

   Description automatically generated**KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research